Clinical Trials Logo

Nervous System Diseases clinical trials

View clinical trials related to Nervous System Diseases.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05212727 Suspended - Clinical trials for Neurological Disorders

Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders

Start date: April 15, 2022
Phase:
Study type: Observational

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by neurological disorders and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of neurological disorders and associated cognitive changes.

NCT ID: NCT04912115 Suspended - Clinical trials for Nervous System Diseases

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

Start date: October 5, 2021
Phase: Phase 2
Study type: Interventional

A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo-Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa-Induced Dyskinesia in Subjects with Parkinson's Disease.

NCT ID: NCT03098732 Suspended - Stroke, Acute Clinical Trials

Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial

MEDIS
Start date: March 22, 2017
Phase: N/A
Study type: Interventional

The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation 30-90 minutes after the completion of tPA infusion than subjects treated with IV tPA (plus sham device). Safety of the MED System Procedure will be evaluated by the incidence of symptomatic PH-2 haemorrhagic transformation within 24 hours following the procedure. Lastly, a health economics study will be conducted to estimate health care costs for each treatment.